Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 0899 • ACR Convergence 2021
Comparison of Sacroiliac CT Findings in Patients with and Without Ankylosing Spondylitis Aged 50 Years or Older: Preliminary Results of the CASIAGE Study
Olivier Fakih, Mickaël Chouk, Clement Prati, Daniel Wendling and Frank Verhoeven, Service de rhumatologie, CHU de Besançon, Besançon, France
Background/Purpose: Diagnosis of axial spondyloarthritis (SpA) is nowadays commonly made with pelvic radiography or MRI. However, there is an important inter-observer variability for radiographs, and…
Abstract Number: 0922 • ACR Convergence 2021
Bimekizumab Shows Sustained and Meaningful Long-Term Improvements in Health-Related Quality of Life in Ankylosing Spondylitis: Interim Results After 3 Years of Treatment in an Ongoing Phase 2b Study
Atul Deodhar¹, Maxime Dougados², Karl Gaffney³, Raj Sengupta⁴, Marina Magrey⁵, Natasha de Peyrecave⁶, Marga Oortgiesen⁷, Thomas Vaux⁸, Carmen Fleurinck⁶, Vanessa Taieb⁸, Christine de la Loge⁹ and Xenofon Baraliakos¹⁰, ¹Oregon Health & Science University, Portland, OR, ²Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, ³Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom, ⁴The Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁵Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, USA, Richfield, OH, ⁶UCB Pharma, Brussels, Belgium, ⁷UCB Pharma, Raleigh, NC, ⁸UCB Pharma, Slough, United Kingdom, ⁹PCOM Analytics, Avallon, France, Avallon, France, ¹⁰Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17F and IL-17A, has been demonstrated to be efficacious and well tolerated in…
Abstract Number: 1318 • ACR Convergence 2021
Interplay Between Covid-19 and Spondyloarthritis or Its Treatment
Richard Howard¹, Michael Weisman², Hedley Hamilton³, Cassie Shafer¹, Elin Aslanyan¹, John Reveille⁴, Kevin Winthrop⁵, Dongseok Choi⁵, Kimbery Ogle⁵, Sarah Siegel⁵, Emily Papaspyru³, Donna Grims¹ and James T. Rosenbaum⁶, ¹Spondylitis Association of America, Encino, CA, ²Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ³Any-3, London, United Kingdom, ⁴Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁵Oregon Health & Science University, Portland, OR, ⁶Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health & Sciences University and Chair Emeritus, Legacy Devers Eye Institute, Portland, OR
Background/Purpose: The Covid-19 pandemic has been especially challenging for patients with inflammatory diseases including spondyloarthritis (SpA). Patients with rheumatic and musculoskeletal diseases (RMDs) remain at…
Abstract Number: 0157 • ACR Convergence 2021
Development of a Deep Learning Algorithm for the Detection of Sacroiliitis on MRI in Patients with Active Axial Spondyloarthritis
Joeri Nicolaes¹, Pedro Machado², Xenofon Baraliakos³, Mayank Santosh⁴, Andrew Carnell⁴, Natasha de Peyrecave⁴ and Alexander Bennett⁵, ¹UCB Pharma, Brussels, Belgium; Medical Image Computing, ESAT-PSI, Department of Electrical Engineering, KU Leuven, Leuven, Belgium, ²Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ⁴UCB Pharma, Brussels, Belgium, ⁵Academic Department of Military Rehabilitation, Defence Medical Rehabilitation Centre Headley Court, Epsom, UK; National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, United Kingdom
Background/Purpose: Magnetic resonance imaging (MRI) plays a critical role in assisting the diagnosis of axial spondyloarthritis (axSpA). There are many characteristic MRI lesions that can…
Abstract Number: 0384 • ACR Convergence 2021
A Tough Cell: The Argument for a Biomarker of Clinical and Imaging Outcomes in Spondyloarthritis: The Neutrophil Lymphocyte Ratio and the Platelet Lymphocyte Ratio
Rouhin Sen¹, Emmeline Kim², Elizabeth Cheng³, Kavya Ganuthula⁴, Meika Fang⁵, Gail Kerr⁶, Jessica Walsh⁷, Elizabeth Chang⁸, Siba Raychaudhuri⁹, Andreas Reimold¹⁰ and Liron Caplan¹¹, ¹University of Colorado School of Medicine/Rocky Mountain Regional Veterans Affairs Medical Center (VAMC), Denver, CO, ²University of Colorado School of Medicine, Aurora, CO, ³Rocky Mountain Regional VAMC, Aurora, CO, ⁴Rocky Mountain Regional VAMC/University of Colorado School of Medicine, Aurora, CO, ⁵David Geffen School of Medicine at UCLA/West Los Angeles Veterans Affairs Medical Center (VAMC), Los Angeles, CA, ⁶Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC, ⁷Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ⁸Phoenix Veterans Affairs Medical Center (VAMC), Phoenix, AZ, ⁹Sacramento Veterans Affairs Medical Center (VAMC)/University of California-Davis Health, Davis, CA, ¹⁰University of Texas – Southwestern Medical Center/Dallas Veterans Affairs Medical Center (VAMC), Dallas, TX, ¹¹Rocky Mountain Regional Veterans Affairs Medical Center (VAMC)/University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Biomarkers of disease activity/severity and imaging outcomes in axial spondyloarthritis (axSpA) remain a challenge. The most common relevant biomarker is the C-Reactive Protein (CRP),…
Abstract Number: 0900 • ACR Convergence 2021
The Phenomenon of Fused Sacroiliac Joints but Absent Syndesmophytes in Long Standing Ankylosing Spondylitis Patients: Data from a Prospectively Followed Cohort
Lauren Ridley¹, Mark Hwang², John Reveille³, Lianne Gensler⁴, Mariko Ishimori⁵, Matthew Brown⁶, Mohammad Rahbar⁷, Amirali Tahanan⁸, Michael Ward⁹, Michael Weisman¹⁰ and Thomas Learch¹¹, ¹McGovern Medical School, Katy, TX, ²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ³Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁴Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁵Cedars-Sinai Health System, Los Angeles, CA, ⁶King's College London, London, United Kingdom, ⁷Division of Clinical and Translational Sciences, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, ⁸McGovern Medical School, Houston, TX, ⁹Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, United States, Rockville, MD, ¹⁰Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹¹Cedars-Sinai, Los Angeles, CA
Background/Purpose: Ankylosing Spondylitis describes disorders of inflammation and damage to the spine and sacroiliac (SI) joints. Clinicians have observed, on occasion, AS subjects with fused…
Abstract Number: 0923 • ACR Convergence 2021
Minimal Impact of the COVID-19 Pandemic on Patient-Reported Disease Activity and Health-Related Quality of Life in Patients with Ankylosing Spondylitis Receiving Bimekizumab: Post Hoc Analyses from a Phase 2b Study
Philip Robinson¹, Pedro Machado², Nigil Haroon³, Lianne Gensler⁴, John Reveille⁵, Vanessa Taieb⁶, Thomas Vaux⁶, Carmen Fleurinck⁷, Marga Oortgiesen⁸, Natasha de Peyrecave⁷ and Atul Deodhar⁹, ¹University of Queensland School of Clinical Medicine, Brisbane, Queensland, Australia, Herston, Australia, ²Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ³Division of Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁵Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Raleigh, NC, ⁹Oregon Health & Science University, Portland, OR
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that inhibits both interleukin (IL)-17A and IL-17F, has been demonstrated to be efficacious and well tolerated in patients…
Abstract Number: 1322 • ACR Convergence 2021
Body Mass Index (BMI) Underestimates Obesity in Females with Axial Spondyloarthropathy
Sinead Maguire¹, Wilson Fiona², Phil Gallagher³ and Finbar (Barry) O'Shea¹, ¹St James's Hospital, Dublin, Ireland, ²Discipline of Physiotherapy, Trinity College Dublin, Dublin, Ireland, ³St Vincent's Hospital, Dublin, Ireland
Background/Purpose: Worldwide prevalence of obesity has been steadily increasing, despite public health campaigns to raise awareness. In axial spondyloarthropathy (axSpA) obesity has been shown to…
Abstract Number: 0158 • ACR Convergence 2021
The Influence of Age on the Prevalence of Inflammatory and Post-inflammatory MRI Lesions in the Sacroiliac Joints of Patients with and Without Axial Spondyloarthritis
Xenofon Baraliakos, Styliani Tsiami, Anna Kühn, Martin Fruth and Jürgen Braun, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is clinically characterized by chronic inflammatory back pain and by inflammatory and structural changes in the sacroiliac joint (SIJ) as assessed…
Abstract Number: 0385 • ACR Convergence 2021
The Diagnostic Utility of Serum interleukin-22 in Patients with Suspected Axial Spondyloarthritis
Michal Sagiv¹, Abid Awisat², Aniela Shouval², Regina Peri³, Mohammad Adawi⁴, Firas Sabbah⁴, Itzhak Rosner², Aharon Kessel³ and Gleb Slobodin², ¹Faculty of Medicine, Bar Ilan University, Tel Aviv, Israel, ²Rheumatology Unit, Bnai Zion Medical Center, Haifa, Israel, ³Clinical Immunology and Allergy Division, Bnai Zion Medical Center, Haifa, Israel, ⁴Puria Medical Center, Tiberias, Israel
Background/Purpose: There is an unmet need for a reliable biomarker for the diagnosis and differentiation of AxSpA from its multiple mimickers. Serum levels of IL-22,…
Abstract Number: 0901 • ACR Convergence 2021
Low Dose Dual Energy CT Scan for the Detection of Bone Marrow Edema and Erosions in Axial Spondyloarthritis
Jonathan Chan¹, Savvas Nicolaou¹, Yet Yen Yan², Mahomed Osman³, Hugue Ouellette¹ and Sabeena Jalal⁴, ¹University of British Columbia, Vancouver, BC, Canada, ²Changi General Hospital, Singapore, ³Queensland X-ray, Brisbane, Australia, ⁴Harvard School of Public Health, Boston, USA, Boston, MA
Background/Purpose: Bone marrow edema (BME) and erosions of the sacroiliac (SI) joints are key imaging features in the diagnosis of axial spondyloarthritis (axSpA). MRI with…
Abstract Number: 0927 • ACR Convergence 2021
Whole Blood Transcriptional Changes Following Treatment with Filgotinib in Patients with Ankylosing Spondylitis
Denis Poddubnyy¹, Yihua Liu², William Barchuk³, Robin Besuyen⁴, René Galien⁵, Yuan Tian², Vlad Malkov² and Angie Hertz², ¹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ²Gilead Sciences, Foster City, CA, ³Gilead Sciences, Inc., Foster City, CA, ⁴Galapagos BV, Leiden, Netherlands, ⁵Galapagos NV, Romainvulle, France
Background/Purpose: Ankylosing spondylitis (AS) – also referred to as radiographic axial spondyloarthritis – is a chronic inflammatory disease that affects the sacroiliac joints and spine.…
Abstract Number: 1361 • ACR Convergence 2021
Impact of Intermediate Treatment Interruption on Secukinumab Efficacy in Patients with Active Psoriatic Arthritis and Ankylosing Spondylitis: Interim Analysis Results from the SERENA Study
Uta Kiltz¹, Petros Sfikakis², Nicola Gullick³, Gkikas Katsifis⁴, Anna Kandyli⁵, Jan Brandt-Jrgens⁶, Philippe Goupille⁷, Nicola Maiden⁸, Karl Gaffney⁹, Maher Aassi¹⁰, Barbara Schulz¹⁰, Effie Pournara¹⁰ and Piotr Jagiello¹⁰, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²National Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ³University Hospitals Coventry & Warwickshire, Coventry, United Kingdom, ⁴Rheumatology Clinic Naval Hospital of Athens, Athens, Greece, ⁵Rheumatology Outpatient Clinic, Iaso General Hospital, Athens, Greece, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷University hospital of Tours, Rheumatology department, Tours, France, ⁸Craigavon Area Hospital, Southern Health & Social Care Trust, Portadown, Craigavon BT63 5QQ, Craigavon, United Kingdom, ⁹Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom, ¹⁰Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC) has demonstrated long-lasting efficacy and a favorable safety profile in patients (pts) with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) across Phase…
Abstract Number: 0159 • ACR Convergence 2021
Structural Damage in Axial Spondyloarthritis: Is There a Preferred Way to Assess Progression over Time?
Xenofon Baraliakos¹, Valeria Rios Rodriguez², Murat Torgutalp², Anil Dilbaryan², Hildrun Haibel³, Maryna Verba⁴, Joachim Sieper³, Jürgen Braun¹, Martin Rudwaleit⁵ and Denis Poddubnyy⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Charité University Medicine Berlin, Berlin, Germany, ³Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ⁵University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁶Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: The aim of this study is to investigate the performance of the modified Stokes Ankylosing Spondylitis Scoring System (mSASSS) in assessing spinal radiographic damage…
Abstract Number: 0386 • ACR Convergence 2021
Delay to Diagnosis in Axial Spondyloarthritis: The Gap Is Closing, but Persistent Association with Severe Disease
Maria McWalter¹, Conall MacGearailt¹, Sinead Maguire², Finbar (Barry) O'Shea² and Gillian Fitzgerald³, ¹Galway University Hospitals, Galway, Ireland, ²St James's Hospital, Dublin, Ireland, ³Galway University Hospital, Galway, Ireland
Background/Purpose: Diagnostic delay in axial spondyloarthritis (axSpA) presents a challenge in the management of the condition, despite increased awareness. Reducing the gap between symptom onset…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].